ArriVent BioPharma (AVBP) Restructuring Costs (2024 - 2026)

ArriVent BioPharma (AVBP) has 3 years of Restructuring Costs data on file, last reported at $2.3 million in Q1 2026.

• For the quarter ending Q1 2026, Restructuring Costs rose 7.44% year-over-year to $2.3 million; the trailing twelve-month figure through Mar 2026 stood at $8.9 million (up 17.2% YoY), and the FY2025 full-year result was $8.8 million, up 22.77% from the prior year.
• Restructuring Costs climbed to $2.3 million in Q1 2026, from $2.3 million in the prior quarter.
• In the past five years, Restructuring Costs ranged from a high of $2.4 million in Q2 2025 to a low of $1.5 million in Q4 2024.
• A 3-year average of $2.0 million and a median of $2.1 million in 2024 frame the typical range for Restructuring Costs.
• Peak annual rise in Restructuring Costs reached 54.86% in 2025, while the deepest fall reached 7.37% in 2025.
• Tracing AVBP's Restructuring Costs over 3 years: stood at $1.5 million in 2024, then surged by 54.86% to $2.3 million in 2025, then climbed by 2.21% to $2.3 million in 2026.
• Business Quant data shows AVBP's Restructuring Costs at $2.3 million in Q1 2026, $2.3 million in Q4 2025, and $1.9 million in Q3 2025.